The Supervisory Board of M1 Kliniken AG has appointed Katharina Zimmnau to the company's Executive Board effective December 10, 2025. Zimmnau has served as Chief Financial Officer of M1 Kliniken AG since June 1, 2025, bringing extensive experience in accounting, controlling, and process design to her expanded role.
This appointment represents a strategic reinforcement of leadership at a critical juncture for the medical aesthetics provider. As the leading fully integrated provider of medical aesthetic services in Europe and Australia, M1 Kliniken AG operates 58 clinics across ten countries under the M1 Med Beauty brand. The company's expansion since late 2018 has established a foundation for scalable future growth and further development of its global market position.
Attila Strauss, CEO of M1 Kliniken AG, emphasized the importance of Zimmnau's appointment to the company's continued development. "I am very pleased to welcome Ms. Zimmnau to the team. With her many years of experience in accounting, controlling, and process design, she will play a key role in shaping the further development of our profitable growth trajectory," Strauss stated.
The board expansion comes as M1 Kliniken AG maintains its strategic focus on high standardization and consistent scalability across its international operations. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards while being offered at market-leading prices. This operational model has positioned the company as a significant player in the growing medical aesthetics industry.
M1 Kliniken AG's portfolio includes the M1 Schlossklinik in Berlin, which operates as one of Europe's largest and most modern clinics for plastic and aesthetic surgery. The facility features four operating theaters and 35 beds, representing the company's commitment to comprehensive medical aesthetics services. The original release announcing Zimmnau's appointment can be viewed on www.newmediawire.com.
For investors and industry observers, this leadership development signals M1 Kliniken AG's commitment to strengthening its management structure as it pursues further international expansion. The appointment of an experienced financial executive to the board suggests increased focus on financial discipline and strategic resource allocation during the company's growth phase. In the competitive medical aesthetics sector, where standardization and scalability are crucial for profitability, experienced leadership in financial operations and process design can provide significant competitive advantages.
The medical aesthetics market continues to experience substantial growth globally, driven by increasing consumer demand and technological advancements. M1 Kliniken AG's expansion across Europe and Australia positions the company to capitalize on this trend, with the strengthened management board now better equipped to oversee complex international operations. The company's model of physician-performed treatments at market-leading prices addresses growing consumer concerns about safety and affordability in aesthetic procedures.
This board appointment reflects broader trends in the healthcare sector where specialized providers are strengthening leadership teams to manage expansion while maintaining quality standards. For patients seeking aesthetic treatments, strong corporate governance and financial stability at providers like M1 Kliniken AG can translate into greater confidence in the safety and longevity of the services offered. The company's continued focus on physician-led care distinguishes it in a market where regulatory oversight and quality standards vary significantly by region.
